MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS
Conference
Bell, Erica H, Zhang, Peixin, Fisher, Barbara J et al. (2016). MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS
. NEURO-ONCOLOGY, 18 115-115.
Bell, Erica H, Zhang, Peixin, Fisher, Barbara J et al. (2016). MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS
. NEURO-ONCOLOGY, 18 115-115.